(PharmaNewsWire.Com, July 15, 2017 ) Venous thromboembolism (VTE) , which is composed of deep vein thrombosis (DVT) and pulmonary embolism (PE) , is a blood clot (thrombosis) of the circulatory system that leads to impeded blood flow, which can have serious consequences in affected individuals. VTE can occur at any age, but it is more common in adults ages 60 years and older and is very rare in children. VTE events are highly dangerous and are associated with high rates of mortality and morbidity.
Publisher epidemiologists forecast an increase in the diagnosed incident cases of VTE in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) , from 896,377 cases in 2016 to 1,071,438 in 2026, at an Annual Growth Rate (AGR) of 1.95%.The number of VTE attacks is forecast to grow from 1,020,991 in 2016 to 1,224,696 in 2026 in the 7MM. Publisher epidemiologists have identified the predominant drivers of this market to be changes in country-specific incidence and procedure rates, as well as in the underlying demographic trends.
Publisher epidemiologists forecast the prevalent cases of VTE in the 7MM from 2016-2026 using nationally-representative, country-specific studies published in peer-reviewed journals that provided the age- and sex-specific incidence of VTE, DVT, and PE in the 7MM. Additionally, they forecast the number of VTE attacks, medically ill discharges at risk of VTE, knee and hip replacements, recurrent VTE cases at one and 10 years, and VTE cases with cancer as comorbidity. Publisher epidemiologists ensured that the forecast methodology was consistent across all the 7MM to allow for a meaningful comparison of the diagnosed incident cases of VTE across these markets.
Scope
- The Venous Thromboembolism (VTE) EpiCast Report provides an overview of the risk factors and global trends of VTE in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) . It includes a 10-year epidemiology forecast of diagnosed incident cases of VTE, deep vein thrombosis, and pulmonary embolism segmented by sex and age (in five-year increments beginning at ages zero to four years and ending at 85 years and older) in these seven markets. Additionally, this report includes the number of VTE attacks, medically ill discharges at risk of VTE, primary total knee and hip replacements, recurrent VTE cases after one and 10 years, and diagnosed VTE cases with cancer as comorbidity. - The VTE epidemiology report is written and developed by Masters- and PhD-level epidemiologists. - The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy The VTE EpiCast report will allow you to - - Develop business strategies by understanding the trends shaping and driving the global VTE market. - Quantify patient populations in the global VTE market to improve product design, pricing, and launch plans. - Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for VTE therapeutics in each of the markets covered. - Identify the percentage of VTE cases with recurrence of VTE and percentage of VTE cases with cancer as comorbidity Table of Content: 1.1 List of Tables 3 1.2 List of Figures 3 2 Venous Thromboembolism: Executive Summary 4 2.1 Related Reports 6 2.2 Upcoming Related Reports 6 3 Introduction 7 3.1 Disease Background 7 3.2 Risk Factors and Comorbidities 8 3.3 Global and Historical Trends 9 3.4 Forecast Methodology 11 3.4.1 Sources 11 3.4.2 Forecast Assumptions and Methods 13 3.5 Epidemiological Forecast for VTE (2016-2026) 24 3.5.1 Diagnosed Incident Cases of Pulmonary Embolism 24 3.5.2 Diagnosed Incident Cases of Deep Vein Thrombosis 25 3.5.3 Diagnosed Incident Cases of VTE 26 3.5.4 Age-Specific Diagnosed Incident Cases of VTE 28 3.5.5 Sex-Specific Diagnosed Incident Cases of VTE 29 3.5.6 One- and 10-Year First Time Recurrent Cases of VTE 29 3.5.7 Number of VTE Cases with Cancer as Comorbidity 30 3.5.8 Number of VTE Attacks 31 3.5.9 Number of Hospital Discharges Meeting Criteria for Medically Ill and Those at Risk for VTE 31 3.5.10 Number of Primary Total Knee Replacements and Revisions 32 3.5.11 Number of Hip Replacements 33 3.6 Discussion 34 3.6.1 Epidemiological Forecast Insight 34 3.6.2 Limitations of the Analysis 35 3.6.3 Strengths of the Analysis 35 4 Appendix 36 4.1 Bibliography 36 4.2 Physicians and Specialists Included in this Study 38 4.3 Primary Research - Key Opinion Leaders Interviewed for this Report 40 4.4 About the Authors 43 4.4.1 Epidemiologist 43 4.4.2 Reviewers 43 4.4.3 Global Director of Therapy Analysis and Epidemiology 44 4.4.4 Global Head and EVP of Healthcare Operations and Strategy 44 4.5 About Publisher 44 4.6 Contact Us 45 4.7 Disclaimer 45 Inquire for Report at http://www.reportsweb.com/inquiry&RW0001851106/buying
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
